Waldenstrom Macroglobulinemia clinical trials at University of California Health
5 in progress, 2 open to eligible people
A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies
open to eligible people ages 18 years and up
This is a Phase 1 study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of VLS-101, an antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1) on cancer cells. The study is evaluating VLS-101 in patients with previously treated hematological cancers.
at UCLA UCSD
A Study of ARQ 531 in Patients With Selected Hematologic Malignancies
open to eligible people ages 18 years and up
This is an open-label, multi-center Phase 1/2 study of ARQ 531 in patients with selected hematologic malignancies.
at UCLA
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Sorry, accepting new patients by invitation only
The purpose of this study is to collect long-term safety and efficacy data for participants treated with PCI-32765 (Ibrutinib) and to provide ongoing access to PCI-32765 for participants who are currently enrolled in PCI-32765 studies that have been completed according to the parent protocol, are actively receiving treatment with PCI-32765, and who continue to benefit from PCI-32765 treatment.
at UCLA UCSD
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
Sorry, in progress, not accepting new patients
This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 (Zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
at UCSD
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Sorry, in progress, not accepting new patients
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
at UCLA
Last updated: